• Capricor (CAPR) Phase 1/2 Results of CAP-1002 for Duchenne muscular dystrophy associated cardiomyopathy

       (0 reviews)

    Biotech Forecast
    Clinical and Regulatory
    Event Type: Phase 1/2 Results
    Timing: Q1 2017
    Designation(s): Orphan Drug

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Other
    Indication: Duchenne muscular dystrophy associated cardiomyopathy
    Lead Indication?: Yes
    Treatment Name: CAP-1002

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Capricor Therapeutics
    Stock Symbol: CAPR
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://irdirect.net/pr/release/id/1821526
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement


    With heart disease being one of the primary drivers of death and disability in older DMD patients, each step we take toward better managing DMD is an important one. We look forward to sharing additional milestones from the HOPE-Duchenne trial in the coming months, including its top-line results, which are expected in the first quarter of 2017.


      Report Event

    User Feedback

    There are no reviews to display.